IPD | Cases | Controls | Crude VE (%) | 95%CI | Adjusted VE (%) | 95%CI |
---|---|---|---|---|---|---|
Serotypes PPV23 | 847 | 204 | 42.9 | (21.7 to 58.3) | 39.0a | (15.5 to 55.9) |
75–84 | 540 | 133 | 44.9 | (18.5 to 62.8) | 42.4b | (13.7 to 61.6) |
85+ | 307 | 71 | 39.5 | (−2.5 to 64.3) | 33.9 b | (−15.2 to 62.1) |
Female | 263 | 82 | 46.1 | (9.5 to 68.0) | 38.7c | (−4.9 to 64.2) |
Male | 584 | 122 | 42.5 | (14.3 to 61.4) | 38.0c | (6.4 to 59.0) |
Without HRMC | 390 | 95 | 57.6 | (32.3 to 73.4) | 56.5d | (29.6 to 73.1) |
With HRMC | 425 | 108 | 27.5 | (−11.7 to 52.9) | 20.4d | (−24.5 to 49.1) |
> 5 years after vaccination | 668 | 143 | 44.7 | (9.1 to 66.4) | 15.5a | (−47.1 to 51.4) |
≤ 5 years after vaccination | 777 | 179 | 42.1 | (17.7 to 59.2) | 44.9a | (20.8 to 61.7) |
Serotypes PPV23-non PCV13 | 83 | 204 | 72.2 | (47.3 to 85.3) | 71.5a | (44.2 to 85.4) |
Serotype PCV13 (without 6A) | 764 | 204 | 39.0 | (16.3 o 55.6) | 35.3a | (10.1 to 53.4) |
serotype 3 | 173 | 204 | 39.4 | (7.2 to 60.4) | 36.8a | (0.4 to 59.9) |
Serotype14 | 181 | 204 | 36.9 | (4.1 to 58.5) | 38.8a | (4.1 to 61.0) |
serotype 23F | 153 | 204 | 27.3 | (−12.2 to 52.9) | 11.3a | (−42.1 to 44.7) |
serotype 19F | 69 | 204 | 40.0 | (−7.6 to 66.5) | 34.9a | (−21.3 to 65.1) |
serotype 19A | 68 | 204 | 57.8 | (21.1 to 77.4) | 56.3a | (16.1 to 77.2) |
serotype 6B | 70 | 204 | 52.5 | (13.1 to 74.0) | 51.9a | (8.1 to 74.8) |
serotype 15B | 23 | 204 | 79.4 | (28.5 to 94.1) | 80.6a | (28.6 to 94.7) |
serotype 9 V | 33 | 204 | 31.4 | (−49.0 to 68.4) | 31.3a | (−60.4 to 70.6) |